NewHavenBIZ

n e w h a v e n b i z . c o m | J u n e 2 0 2 2 | n e w h a v e n B I Z 23 P O W E R 2 5 : H e a l t h c a r e 2 0 2 2 natural creams and lotions for sensitive skin. Azitra has also been part of a team working to develop a long-duration mosquito repellent, using the good bacteria living on skin, for the U.S. military. Prior to leading Complexa, Salva was a founder and vice president of operations at Acerta Pharma, which AstraZeneca acquired for $4 billion. Before that, he was senior director of corporate development at Pharmacyclics, where, according to Azitra, he participated in a strategic turnaround that contributed to the company's $21 billion acquisition by AbbVie. Deborah Rathjen, Executive Chair, Bioasis As the leader of New Haven-based Bioasis Technologies Inc., Executive Chair Deborah Rathjen continues to secure international interest in the biopharmaceutical company's technology. In its most recent deal, Bioasis in May entered into a research collaboration and license agreement valued at more than $72 million with Neuramedy Co. Ltd., of Seoul, Korea. Neuramedy is a biotech company researching and developing remedies for neurodegenerative diseases, including Parkinson's disease. Bioasis has teamed up with other companies interested in its technology in recent months, such as Belgium-based Janssen Biotech, UK-based Oxyrane UK Ltd., and Italy's Chiesi Global Rare Diseases, all of which aim to leverage Bioasis' tech to fight diseases. Bioasis is developing its xB3TM platform for delivering therapeutics across the brain's filtering mechanism, or the blood-brain barrier. According to the company, this barrier plays a key role in protecting the brain from blood-borne disease and toxic compounds. e ability to get medicine across this barrier has been a challenge, but doing so is important for treating many neurological conditions, from brain cancer to neurodegenerative diseases. Bioasis' drug-development efforts focus on treatments for brain cancers and ailments such as Gaucher's and Parkinson's diseases, Lewy Body Dementia, multiple sclerosis and epilepsy. According to Rathjen, Bioasis' technology has the potential to "significantly advance" the treatment of neurodegenerative diseases. Forming partnerships with companies around the world is an important part of Bioasis' strategy, she said. Prior to joining Bioasis, Rathjen had been CEO and managing director at Bionomics. Before that, she worked at Peptech Ltd., where she was general manager of business development and licensing. Marc Dunoyer, CEO, Alexion, AstraZeneca Rare Disease Longtime AstraZeneca executive Marc Dunoyer became CEO of Alexion, AstraZeneca Rare Disease last year aer AstraZen- eca acquired the company in a $39 billion deal. In April, Alex- ion announced its plans to expand its presence in New Haven with space at the new bioscience tower current- ly under construction at 101 College St. e company is headquartered in Boston, but has a New Haven presence, with roughly 500 employees working at its research facility at the existing tower next door, at 100 College St. Alexion indicated it expects to occupy the new space by the end of 2023. e expansion is expected to grow the com- pany's research capabilities and double its lab floor space. Under Dunoyer's leadership, Alexion indicated in April it is filling 50 open positions in New Haven, with more hiring on the horizon as the company continues its planned growth in research and development here. Coinciding with the local expansion, AstraZeneca in April announced plans to open a new headquarters for its Alex- ion Rare Disease group and a strategic R&D center in the Boston area by 2026. Alexion has developed treatments for a range of disorders and diseases and has five medicines approved currently, including Kanuma, Koselugo, Soliris, Strensiq and Ultomiris, according to its website. In May, Ultomiris was approved for use in adults with a common form of myasthenia gravis, which can lead to a debilitating loss of muscle function and severe weakness. It impacts roughly 90,000 people in the U.S. Dunoyer's leadership roles have also included serving as AstraZeneca's chief financial officer. He has had a lengthy career in the pharmaceutical indus- try, including stints at Roussel Uclaf, Hoechst Marion Roussel and GSK. Holly Sheffield, President, CooperSurgical Holly Sheffield has been leading Trumbull-based CooperSurgical during a period of growth and acquisition. CooperSurgical is focused on ad- vancing the health of women, babies and families, and its products in- clude an array of medical devices, such as vacu- um-assisted infant delivery devices and amniocentesis needles. is past November, CooperSurgical announced it had reached an agreement to acquire a fertility company, Generate Life Sciences, for $1.6 billion, and the deal was finalized in December. Gen- erate Life Sciences, based in California, provides donor egg and sperm for fertil- ity treatments, fertility cryopreservation services, and storage of newborn stem cells from cord blood and tissue. is was one of several recent acquisi- tions for CooperSurgical. It previously bought UK-based Safe Obstetric Systems for around $52 mil- lion. It purchased a California company, Aegea Medical, that has developed a device to treat heavy menstrual bleed- ing. It acquired an Illinois company called Embryo Options, which partners with fertility clinics to help patients with management and disposition decisions related to frozen embryos, eggs and sperm. Sheffield was named president of CooperSurgical in July 2020, having previously joined its parent, Cooper- Companies, as executive vice president and chief strategy officer in 2018. e California-based CooperCom- panies has two divisions, CooperSur- gical and CooperVision, with the latter focused on vision-related products. Prior to joining the company, Sheffield had more than two decades of experi- ence in investment banking, with a focus on medical equipment and technology. Dave Scott, President & CEO, Hyperfine Inc. Dave Scott took over as president and CEO of Hyperfine Inc. in June 2021, and the company's international impact has been accelerating. e Guilford-based company man- ufactures a compact, portable magnetic reso- nance imaging device called "Swoop." It can be wheeled to a patient's bedside and plugged into a standard wall outlet. According to the company, the technology helps make diagnosis and potential treatment of disease faster and easier than with tradi- tional MRI machines. In November, the Bill & Melinda Gates Foundation awarded a $3.3 million grant to Hyperfine to expand a global research program on the use of Swoop in developing countries. Late last year, Hyperfine announced it was teaming up with the New York- based Brain Tumor Foundation to provide access to free brain scans through BTF's Road to Early Detection campaign. Canadian health authorities in De- cember licensed Hyperfine's portable MRI, opening another market. e license allows the sale in Canada of the latest version of Hyperfine's Swoop MRI machine, which uses deep learning so- ware to improve image quality. Scott's focus in his new role at Hyper- fine has been advancing the company's commercialization and growth strategy, to get more healthcare institutions using Swoop technology globally. When he took the job last year, Scott said he looked forward to helping the company "make its mark on the world" by improving health care for caregivers and patients. Scott's background has included work- ing for Apple, Verb Surgical and Abbott Medical Optics. During his career, Scott has built and led teams working on dig- ital surgery, digital health ecosystems, surgical robotics and medical imaging and diagnostics. Scott has more than 25 patents, including medical technolo- gy-related areas such as X-ray imaging and endoscopy. Jennifer Good, Co- founder, President & CEO, Trevi Therapeutics Jennifer Good leads New Hav- en-based biotech company Trevi erapeutics, which is working to find new uses for the investigational therapy Haduvio. Haduvio is an oral, extended-re- lease formulation of nalbuphine, a drug that has been on the market as an injectable pain treatment for more than 20 years in the United States and Europe. Trevi is investigating Haduvio's use for patients suffering from ailments such as chronic cough and chronic itching. Good serves as president and CEO of the company, which she co-founded in 2011. Good has a long history in the industry, having previously held leadership positions at Penwest Pharma- ceuticals. In April, Trevi announced it had raised $55 million in a private place- ment deal, which will help the company develop Haduvio as a treatment for chronic cough for patients with idio- pathic pulmonary fibrosis (IPF). Trevi reported positive results earlier this year in its Phase 2 trial. According to the company, chronic cough in patients with IPF is a serious complication of a terminal disease, with no currently-approved therapies. Good is a board member of the Friedreich's Ataxia Research Alliance, a patient advocacy group advancing treat- ments for the cure of Friedreich's Ataxia. She is also a board member of the Executive Women in Bio, CT Chapter, and she also serves as a co-chair of the New Haven Regional Bioscience Collab- orative. Dr. Albert Ko, Professor, Yale School of Public Health Dr. Albert Ko has oen been called upon for his expertise in microbial diseases during the COVID-19 pandemic. Ko is the Raj and Indra Nooyi professor of public health at the Yale School of Public Health, and he has been a global voice in the media since COVID-19's emergence. He has been quoted in news stories Continued on next page

• Cover